NYSE:AMAM Ambrx Biopharma - AMAM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ambrx Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.85 -0.03 (-1.60%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.77▼$1.9250-Day Range$0.41▼$4.5452-Week Range$0.38▼$5.12Volume278,240 shsAverage Volume720,049 shsMarket Capitalization$71.45 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ambrx Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside116.2% Upside$4.00 Price TargetShort InterestHealthy1.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.24) to ($0.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector598th out of 1,030 stocksBiological Products, Except Diagnostic Industry92nd out of 169 stocks 3.3 Analyst's Opinion Consensus RatingAmbrx Biopharma has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Ambrx Biopharma has a forecasted upside of 116.2% from its current price of $1.85.Amount of Analyst CoverageAmbrx Biopharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.94% of the float of Ambrx Biopharma has been sold short.Short Interest Ratio / Days to CoverAmbrx Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ambrx Biopharma has recently decreased by 26.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmbrx Biopharma does not currently pay a dividend.Dividend GrowthAmbrx Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMAM. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 21 people have searched for AMAM on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ambrx Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Ambrx Biopharma is held by insiders.Percentage Held by Institutions43.14% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ambrx Biopharma are expected to grow in the coming year, from ($0.24) to ($0.04) per share.Price to Book Value per Share RatioAmbrx Biopharma has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ambrx Biopharma (NYSE:AMAM) StockAmbrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.Read More Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Stock News HeadlinesJanuary 24, 2023 | americanbankingnews.comAmbrx Biopharma (NYSE:AMAM) versus Fennec Pharmaceuticals (NASDAQ:FENC) Head-To-Head SurveyJanuary 18, 2023 | seekingalpha.comAmbrx Biopharma: Some Promise, Much UncertaintyFebruary 2, 2023 | PressReach (Ad)Top Innovation StockToday's stock market report features an AI Robotics tech stock with a $4 million order backlog.January 16, 2023 | finance.yahoo.comThe past year for Ambrx Biopharma (NYSE:AMAM) investors has not been profitableDecember 19, 2022 | msn.comAmbrx Biopharma receives NYSE notice for non-complianceDecember 16, 2022 | finance.yahoo.comAmbrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading PriceDecember 11, 2022 | markets.businessinsider.comCowen & Co. Keeps Their Buy Rating on Ambrx Biopharma (AMAM)December 11, 2022 | finance.yahoo.comMeet the Biotech Stock That Jumped Over 1000% in One DayFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 9, 2022 | benzinga.comThinking about buying stock in Ambrx Biopharma, Plug Power, Hello Group, Credit Suisse, or Carvana?December 9, 2022 | seekingalpha.comAmbrx stock surges 160% as drug shows promise in phase 2 breast cancer trialDecember 9, 2022 | finance.yahoo.comAmbrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer CandidateDecember 9, 2022 | finance.yahoo.comAmbrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 TreatmentDecember 6, 2022 | finance.yahoo.comCan Ambrx Biopharma (NYSE:AMAM) Afford To Invest In Growth?November 29, 2022 | finance.yahoo.comInterim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer SymposiumNovember 14, 2022 | seekingalpha.comWeek In Review: Insilico Signs Six-Drug AI Discovery Deal With Sanofi Worth Up To $1.2 BillionNovember 9, 2022 | finance.yahoo.comAmbrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70November 1, 2022 | finance.yahoo.comAmbrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive OfficerOctober 19, 2022 | finance.yahoo.comAmbrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The ReasonOctober 18, 2022 | finance.yahoo.comAmbrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate UpdateOctober 11, 2022 | finance.yahoo.comAmbrx Biopharma to Host Corporate Update Conference CallAugust 29, 2022 | finance.yahoo.comAmbrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate UpdateAugust 19, 2022 | wsj.comAmbrx Biopharma Inc. ADRAugust 16, 2022 | marketwatch.comAmbrx Biopharma Names Kate Hermans Interim Chief Executive OfficerAugust 16, 2022 | finance.yahoo.comAmbrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng TianJuly 5, 2022 | finance.yahoo.comAmbrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of DirectorsJune 28, 2022 | finance.yahoo.comAmbrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMAM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAM Company Calendar Today2/02/2023Next Earnings (Estimated)4/25/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:AMAM CUSIPN/A CIK1836056 Webambrx.com Phone858-875-2400FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+116.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick RatioN/A Sales & Book Value Annual Sales$7.45 million Price / Sales9.59 Cash FlowN/A Price / Cash FlowN/A Book Value$4.92 per share Price / Book0.38Miscellaneous Outstanding Shares38,620,000Free Float36,648,000Market Cap$71.45 million OptionableNot Optionable Beta-2.17 Key ExecutivesMs. Sonja Nelson CPA (Age 49)Chief Financial & Operating Officer Mr. Daniel J. O'Connor J.D. (Age 57)CEO, Pres & Director Dr. Ying J. Buechler Ph.D.Chief Technology OfficerDr. Shawn Shao-Hui Zhang Ph.D.Chief Scientific OfficerKey CompetitorsOrchard TherapeuticsNASDAQ:ORTXTalaris TherapeuticsNASDAQ:TALSX4 PharmaceuticalsNASDAQ:XFORBrainstorm Cell TherapeuticsNASDAQ:BCLIMiNK TherapeuticsNASDAQ:INKTView All CompetitorsInsiders & InstitutionsCormorant Asset Management LPSold 149,997 shares on 11/14/2022Ownership: 6.050%Renaissance Technologies LLCBought 53,000 shares on 11/14/2022Ownership: 0.166%Royal Bank of CanadaBought 42,453 shares on 11/14/2022Ownership: 0.110%View All Institutional Transactions AMAM Stock - Frequently Asked Questions Should I buy or sell Ambrx Biopharma stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMAM shares. View AMAM analyst ratings or view top-rated stocks. What is Ambrx Biopharma's stock price forecast for 2023? 2 brokers have issued 1-year price targets for Ambrx Biopharma's stock. Their AMAM share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 112.8% from the stock's current price. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts. How have AMAM shares performed in 2023? Ambrx Biopharma's stock was trading at $2.27 on January 1st, 2023. Since then, AMAM shares have decreased by 17.2% and is now trading at $1.88. View the best growth stocks for 2023 here. Are investors shorting Ambrx Biopharma? Ambrx Biopharma saw a decrease in short interest in the month of December. As of December 30th, there was short interest totaling 965,700 shares, a decrease of 48.6% from the December 15th total of 1,880,000 shares. Based on an average trading volume of 3,470,000 shares, the short-interest ratio is presently 0.3 days. Currently, 2.6% of the shares of the stock are sold short. View Ambrx Biopharma's Short Interest. When is Ambrx Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 25th 2023. View our AMAM earnings forecast. When did Ambrx Biopharma IPO? (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO. What is Ambrx Biopharma's stock symbol? Ambrx Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMAM." Who are Ambrx Biopharma's major shareholders? Ambrx Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Ambrx Biopharma? Shares of AMAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ambrx Biopharma's stock price today? One share of AMAM stock can currently be purchased for approximately $1.88. How much money does Ambrx Biopharma make? Ambrx Biopharma (NYSE:AMAM) has a market capitalization of $72.61 million and generates $7.45 million in revenue each year. How can I contact Ambrx Biopharma? The official website for the company is ambrx.com. The company can be reached via phone at 858-875-2400. This page (NYSE:AMAM) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.